Scientists engineer bacteria to target cancer, revealing systemic gaps in biotech innovation
Original framing: “How we are engineering bacteria to eat cancer” — The Conversation - Global
The science of engineering bacteria to target cancer is grounded in synthetic biology and microbiology, with promising results in preclinical trials. However, the long-term safety, efficacy, and scalability of these treatments remain under investigation, and more research is needed to understand their impact on the human microbiome and immune system.
The engineering of bacteria to target cancer is not just a scientific breakthrough but a reflection of deeper systemic issues in biotechnology and global health.
By integrating Indigenous knowledge, promoting open-source innovation, and developing ethical regulatory frameworks, we can move beyond the myth of 'innovation as salvation' and toward a more equitable and holistic approach to disease treatment. The trickster in this story is the very idea that the organisms we fear may hold the key to healing, challenging us to rethink our relationship with nature and technology. Historical parallels with past medical experiments on marginalized communities remind us that progress must be inclusive and just. Only by weaving together scientific, cultural, and ethical dimensions can we truly harness the potential of engineered bacteria for the benefit of all.